Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-06-24 Capital/Financing Update
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated June 24, 2020, for Relay Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, dilution, management discussion and analysis, business description, management, executive compensation, principal stockholders, underwriting, legal matters, and financial statements. This is a comprehensive registration document for a securities offering, not a financial report like an annual or quarterly report, nor an earnings release or other categories. The S-1 registration statement is a capital markets filing related to financing and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, so it is not RPA or RNS. Confidence is high due to clear identification of the form and content.
2020-06-24 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement Amendment No. 1 filed confidentially with the SEC by Relay Therapeutics, Inc. It is related to the registration of securities under the Securities Act of 1933, including details about indemnification of directors and officers, recent sales of unregistered securities, and exhibits such as underwriting agreements and corporate governance documents. This type of filing is a registration statement for an initial public offering or other securities offering, which falls under capital raising activities. It is not an annual or quarterly report, audit report, earnings release, or any other category related to financial performance or governance disclosures. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive filing, not just an announcement or certification.
2020-06-22 English
Regulatory Filings 2020
Regulatory Filings
2020-06-19 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Relay Therapeutics, Inc. It is a draft registration statement for an initial public offering (IPO) under the Securities Act of 1933. The text includes detailed information typical of an IPO prospectus, such as company overview, risk factors, use of proceeds, capitalization, management discussion, executive compensation, and underwriting details. This type of filing is a regulatory filing related to securities registration and offering, not an annual report, earnings release, or other financial report. It is not a report publication announcement since it contains substantive content and is not merely announcing the availability of a report. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like capital/financing update or proxy solicitation. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2020-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.